Transdermal fentanyl for the treatment of cancer pain: A multicenter study
- 10 Downloads
The multicenter clinical trial is to evaluate the effect and side effects of transdermal fentanyl for patients with cancer pain in China.
A total of 458 patients with moderate-to-severe cancer pain enrolled the multicenter study from 16 institutes. They received transdermal fentanyl for at least 15 days (between 15 and 523 days).
Baseline mean of pain intensity was 7. 92 (between 4 and 10). On day 1, 3, 6, 9, 15 and 30, the pain mean scores were decreased to 6. 05, 4.28, 3, 58, 3.06, 1.29 (P<0.001). 86.3% patients reported that the pain intensity decreased was on day 1, and the pain stabilizing control war on day 5. After the pain treatment, the patients' quality of life was significantly improved. The pain intensity (mean score 8.25) was more serious, and the effect of pain treatment was poorer in metastasis bone pain than pain in other anatomic site. The common side effects were constipation, nausea, dizzy, sedation, stomach upset, vomiting and difficulty of urination. The incidence of constipation was related with the age, while the incidence of vomiting and difficulty of urination was related with the gender.
The transdermal fentanyl patch is proving to be a safe, convenient, well tolerated and sustained effective treatment modality in the control of cancer pain.
Key wordscancer pain transdermal fentanyl pain management
Unable to display preview. Download preview PDF.